Hisgade Raises New Funding Round for Glaucoma Microstent

Hisgade has closed a new funding round to advance its glaucoma microstent, according to Dealroom.co.

The round marks the latest capital event for the company, which is developing a microstent device aimed at the surgical treatment of glaucoma. Dealroom.co, which tracks deal activity across European and global startups, listed the funding in its deal database without disclosing the round size, the investors involved, or the company's post-money valuation.

Hisgade's core product targets one of the largest unmet needs in ophthalmology. Glaucoma is a leading cause of irreversible blindness worldwide, and current treatment options — from topical eye drops to invasive filtration surgery — leave significant room for less invasive, more durable surgical alternatives. Microstents, tiny implants designed to drain fluid from the eye and reduce intraocular pressure, sit at the center of that shift toward minimally invasive glaucoma surgery.

The funding round, while undisclosed in size, signals continued investor appetite for medical device companies working in high-burden therapeutic areas. Ophthalmic device developers have attracted steady venture interest in recent years as surgical techniques move toward outpatient, minimally invasive procedures that reduce complication rates and recovery times compared with traditional trabeculectomy.

Dealroom.co's listing did not specify whether the round is an extension of prior financing or a new institutional round, and the company has not publicly named participating investors.

For Hisgade, the new capital is expected to support continued development of the microstent as the company works toward clinical validation and eventual commercialization in a market where device differentiation hinges on safety profiles, ease of implantation and long-term pressure control.